Hemostemix Inc. announced the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed to scale autologous stem cell therapy processes by leveraging robotic-material-handling and parallel- processing efficiencies, duplicating manual methods of angiogenic cell precursor (ACP-01) production. ACTS will scale ACP-01 production to generate the quality and efficacious patient derived stem cell therapeutic.

The proof of principle system will perform the core synergetic cell precursor isolation, its differentiation into ACP-01, and its harvesting into ready-to-use syringes that are couriered to the patient's physician after meeting batch release criteria.